Old versus new medications: How much should be taught?

Academic Psychiatry

Volumn 29, Issue 2, 2005, Pages 162-166

  Jefferson, James W ^a,b,c  

^a Madison Institute of Medicine   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Healthcare Technology Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CHLORAL HYDRATE; CHROMIUM; CLOZAPINE; CONIUM MACULATUM EXTRACT; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PERPHENAZINE; POTASSIUM BROMIDE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE; ANTIDEPRESSANT AGENT;

AKATHISIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; CONIUM; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOMANIA; MANIA; MEDICAL EDUCATION; MEDICAL LITERATURE; META ANALYSIS; MOOD DISORDER; NARCOLEPSY; OBSESSIVE COMPULSIVE DISORDER; PSYCHOPHARMACOLOGY; RESIDENCY EDUCATION; RESIDENT; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TEACHING; WEIGHT GAIN; ARTICLE; DRUG DESIGN; EDUCATION; TIME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; HUMANS; INTERNSHIP AND RESIDENCY; PSYCHOPHARMACOLOGY; TIME FACTORS;

EID: 26944473676     PISSN: 10429670     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ap.29.2.162     Document Type: Review

References (25)

1. Stauss MB (Ed.): Familiar Medical Quotations. Boston, Little, Brown and Company, 1968
2. Jefferson JW: Old drugs for old folks. Geriatric Times 2000; 1:13-14
3. Rush B: Medical Inquiries and Observations upon The Diseases of the Mind (facsimile of the Philadelphia 1812 ed.). New York, Hafner Publishing Company, 1962, 174-213
4. Feldman PE: Ancient psychopharmacotherapy. Bull Menninger Clin 1965; 2:256-263
5. Davidson JRT, Abraham K, Connor KM, et al: Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry 2003; 53:261-264
6. Ban TA: Pharmacotherapy of mental illness: a historical analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 2001; 25:709-727
7. MacLeod N: The bromide sleep: a new departure in the treatment of acute mania. Br Med J 1900; 1:134-136
8. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1994; 15:49-57
9. Warneke, L: A possible new treatment approach to obsessive-compulsive disorder (Letter to Ed.). Can J Psychiatry 1997; 42:667-668
10. Jefferson, JW: Who put the benzedrine in Mrs. Murphy's ovaltine? Geriatric Times 2001; Sept/Oct:9-10
11. Dwight-Johnson M, Lagomasino IT, Simpson GM: Underuse of evidence-based pharmacotherapies for affective disorders. Psychiatr Serv 2003; 54:1076-1078
12. Partial Agonism: Redefining Effectiveness Across the Spectrum of Psychotic Disorders. Irvine, Calif., CME Inc., 2003, pp 1-72
13. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2):596-601
14. Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321:1371-1376
15. Davis JM, Chen N, Glick RD: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564
16. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581-1589
17. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 2003; 290:2693-2702
18. Anderson IM: Meta-analytical studies on new antidepressants. Br Med J 2001; 57:161-178
19. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83:389-400
20. Geddes J, Goodwin G: Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. B J Psychiatry 178(suppl 41):191-194, 2001
21. Goodwin FK: Pharmacotherapy of bipolar disorder: trends and controversies (interview). Currents in Affective Illness 2001; 20:5-11
22. Baldessarini RJ, Tondo L, Hennen J, et al: Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry 2002; 10:59-75
23. Tondo L, Isacsson G, Baldessarini RJ: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17:491-511
24. Healy D: The Anti-Depressant Era. Cambridge, Mass, and London, Harvard University Press, 1997
25. th Edition, N. Y., Oxford University Press, 1992